Agios' PK activator tebapivat looked no better than the first-generation agents in sickle cell disease, although it's awaiting approval for mitapivat in the same condition.
Agios said it is dropping a next-generation sickle cell disease drug after lackluster results from a mid-stage trial.
The drug, known as tebapivat, represented Agios’ …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful…
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated…
Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic…
Agios Pharma (AGIO) stock spikes 15% as FDA grants Priority Review for sickle cell disease drug mitapivat. Details here.
Vertex's Casgevy wins pediatric approval, United Therapeutics buys Thymmune for up to $300M, plus deals from Insilico, Fosun and…
Agios licenses Oscotec’s immune thrombocytopenia drug; CEPI funds three Ebola vaccine candidates; Skyhawk shares Huntington's…
